BLOG

HPTN and MEMOTEXT collaborate on integrated care communications platform

The HIV Prevention Trials Network (HPTN) has launched a research study examining the feasibility and scalability of an integrated, enhanced, case manager care strategy to attain and maintain viral suppression among HIV-infected men who have sex with men (MSM) in the United States. The study is being conducted in four US cities with 356 participants enrolled into the study and randomized to either the case manager intervention or the standard-of-care. Part of this integrated care strategy includes a fully automated, digital communications platform, which MEMOTEXT Corp. was awarded the opportunity to develop after being selected through a rigorous RFP process. The communication platform is a web based, intuitive tool that helps study participants stay engaged in their care. Through the platform, participants can opt to receive medication, appointment or refill reminders and motivational messages via IVR (phone call), SMS (text message) or email at a frequency that is personalized and unique to their needs. Messages are 2-way communications that provide participants with a direct link to their case managers for additional support. The system was custom built by the MEMOTEXT team as per the HPTN study specifications to seamlessly integrate with other aspects of the study and provide real-time feedback and data to study managers and case managers.

The requirements for this system gave both MEMOTEXT and HPTN the chance to develop something completely unique, add to our repertoires of capabilities and build new processes for implementing custom programs.

“Winning an opportunity like this and working with such a great team has been an incredible experience for us” says Amos Adler, president of MEMOTEXT. “We are looking forward to leveraging what we’ve learned and continuing to collaborate together.”

“The HPTN is committed to adding new tools to the HIV prevention toolbox that succeed in clinical trials and can be used in real-world settings,” says Chris Beyrer, MD, MPH, HPTN 078 protocol chair.  “This tool, which is easy to use and tailored for each patient, has the potential to increase drug adherence and, thus, suppress further transmission of the virus.  We are happy to be working with MEMOTEXT on this project, as they have proven to be a reliable, knowledgeable and hard-working partner.”

ABOUT HPTN: The HIV Prevention Trials Network, which is a global entity focused on developing and testing HIV prevention technologies and strategies (for more information, go to www.hptn.org). The HPTN is funded by the U.S. Government via the National Institutes of Health.

ABOUT MEMOTEXT: MEMOTEXT Corp. improves outcomes for patients and the bottom line for healthcare stakeholders by ensuring patients adhere to their treatment. With a proprietary, evidence-based self-learning algorithm and communications platform, MEMOTEXT integrates behavior change into the everyday lives of patients with personalized, secure, interactive voice, text, and mobile communications. Visit us at memotext.com

Comments are closed.

Back to Top